NCT06907251View on ClinicalTrials.gov

Dapagliflozin for Long COVID Syndrome

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2029

Conditions
COVID - 19Long COVID Syndrome
Interventions
DRUG

Dapagliflozin (DAPA)

Dapagliflozin 10mg orally once a day for 12 months

DRUG

Placebo

Participants will receive a matching placebo taken once daily by mouth for 12 months.

Trial Locations (1)

K1Y 4W7

University of Ottawa Heart Institute, Ottawa

All Listed Sponsors
lead

Ottawa Heart Institute Research Corporation

OTHER